Canatu (CANATU) Company Presentation summary

Business overview and technology platform

• Specializes in advanced carbon nanotube (CNT) technology with applications in semiconductor, automotive, and medical diagnostics sectors.

• Holds 130 patents and over 50 patents pending across 38 patent families, supporting a strong competitive moat.

• Employs 127 staff from over 30 nationalities, with mass production since 2015 (automotive) and 2021 (semiconductor).

• Differentiated by proprietary dry deposition CNT technology, offering superior material properties and production efficiency.

• Business model includes recurring revenue from product sales, equipment, and licensing, with long-term customer contracts.

Market focus and growth drivers

• Semiconductor segment contributed ~80% of 2023 revenue, with CNTs used in EUV pellicles and inspection membranes.

• Automotive segment (~20% of 2023 revenue) leverages CNTs for LiDAR and camera heaters, supporting ADAS and EV trends.

• Medical diagnostics is in development, targeting highly sensitive point-of-care (POC) testing with CNT-based biosensors.

• Addressable markets in focus are projected to reach €2–4 billion by 2030, with strong growth in all three sectors.

• Key market drivers include the shift to advanced semiconductors, smart vehicles, and decentralized healthcare diagnostics.

Financial performance and targets

• Achieved rapid revenue growth: €1.5m (2020), €5.5m (2021), €8.4m (2022), €13.6m (2023), with €20–25m forecast for 2024.

• Gross margin improved from 61% (2020) to 71% (2023), supported by high-value, IP-protected products.

• Targets over €100m annual revenue and >30% adjusted EBIT margin by 2027, with semiconductor as the main contributor.

• Current CAPEX levels (€5–6m in 2024) are expected to support scaling to meet long-term targets.

• OPEX growth aligns with headcount expansion; further hiring of 25–35 FTEs annually anticipated.